Skip to content

We believe in novel drug targets mapped to patient biology – maximizing their probability of becoming life-changing treatments

De-risk discovery with mechanistic biomarkers

Developing successful medicines depends on selecting the right target and product profile based on the disease biology of your patients.

Our unique understanding disease biology and in which patients a drug targeting a specific mechanism is going to work informs the selection of targets that are most likely to be successful.

We're the first and only company to unravel many complex diseases, identifying novel genetic associations and new drug targets linked to specific patient subgroups by mechanism of their disease. 

This is precision drug discovery.

31% higher

probability of success with mechanistic understanding of disease biology. 

We go further.

PrecisionLife targets-min

Success from concept to clinic 

Our targets are matched to patient biology and built on deep data packages which contain unique insights , including:

  Target novelty & druggability
  Biomarkers of drug response
  Prediction of clinical efficacy
  Secondary indication potential
  Prevalence & commercial opportunity

These insights better inform target selection, choice of indication, and clinical development - de-risking drug programs from concept to clinic and maximizing their value.

Actively protective drug targets

Mechanisms that protect against development of disease

PrecisionLife is uniquely able to discover actively protective biology – a new class of drug targets providing healthy ageing and longevity opportunities in complex, chronic diseases.

Actively protective drug targets can be drugged by existing modalities or via stimulation of the production of protective proteins to create prophylactic drugs and therapeutic vaccines.

Delaying onset and preventing progression of chronic diseases.

Discover actively protective biology

Actively protective biology drug targets

Our approach

Discover

We identify causal biology across multiple mechanisms and discover novel targets associated with stratified patient populations with distinct disease etiologies.

Select

This enables us to find and validate the best possible targets and link them with mechanistic patient stratification biomarkers to the most scientifically robust patient populations.

Succeed

Our linking of drug target and disease mechanism to the patients who will benefit enables early, informed decisions and selection of targets that are most likely to be successful in trials and on market.

Use cases

Our partnership approach is responsive and scalable, working seamlessly alongside existing discovery and development teams. We support our drug discovery partners in multiple ways:

TPP led discovery 2

TPP-led discovery

We match druggable targets to specified TPPs, which can include drug response, modality, route of administration and other key factors.

The biomarkers that identify target responder populations provide a powerful yet simple inclusion criterion throughout clinical development.

Target-assessment-1

Target evaluation

Our approach provides quick and inexpensive assurance of an existing target’s causal genetic linkage to the disease and the prevalence of the target within the patient population.

We provide biomarkers and insights for downstream clinical development, regulatory strategy, and marketing.

Subgroup discovery-1

Subgroup discovery

We're unique in our ability to stratify disease populations by causal biology of disease.

This enables discovery of distinct clinically relevant patient subgroups with mechanism-based biomarkers to link patients to the targets and treatments they will respond to.

Protective targets-1

Protective targets

Actively protective biology opens up a new class of protective drug targets providing healthy aging opportunities for complex diseases.

The targets can be drugged by existing modalities or via stimulation of the production of protective proteins using therapeutic mRNA or DNA vaccines.

Drug positioning-1

Drug positioning

We identify a target's most scientifically and commercially attractive indications and patient subgroups. 

We achieve this with unique biomarkers and insights into causal genetics, mechanistic explanation of clinical phenotype, mechanistic prevalence, and secondary indication potential.

"PrecisionLife supports our approach to identify the right drug target and patient subgroups and increase our probability of success to provide more effective treatments for patients."

Matt Barnes
EVP, President and Head of R&D
Nxera Pharma

The PrecisionLife difference

With an unparalleled understanding of complex disease biology, we identify the causal drivers of disease onset and progression, with biomarkers to stratify patients with the underlying mechanisms to develop better drugs, faster.

First in class

Be first-in-class

Our insights enable you to successfully target novel mechanisms of action, address previously untreatable conditions and offer significant advantages over existing treatments.

 

Reduce time and cost

Reduce time & cost

Our biomarkers de-risk drug programs, guide better target selection, smaller and more efficient clinical trials, and support faster approvals and market adoption.

Maximize success

Maximize success

Our unique ability to map targets, trials, and treatments to patients by disease mechanism maximizes the likelihood of achieving positive efficacy endpoints and regulatory approvals.

Let's talk

Patients are counting on us

If you’re developing new drug targets for complex diseases, we’d love to show you how our unique patient stratification insights can help accelerate your work.

Contact us to request more information, arrange a meeting or discuss a collaboration.